Why you should care about Virgin IPO
In the biggest IPO of the year, the Bain Capital-owned airline has decided to return to the ASX amid a rise in domestic tourism and spending.
The offer will almost halve Bain's stake in the airline from about 70 per cent to 39.4 per cent.
Qatar Airlines, which recently invested in Virgin, will reportedly keep its 23 per cent holding.
If successful, Virgin's listing in the market will be seen as a sign of a bright future for the Australian economy, as investors signpost the potential for the nation's consumer spending to recover.
If it fails, it could point to the opposite. The performance of Virgin's IPO could reflect the sentiment surrounding the future of the Australian economy. NewsWire / Nicholas Eagar Credit: Supplied
So far, all signs point to a successful IPO, as domestic travel demand recovers and the two recent RBA rate cuts ease the pressure on Australian households.
Qantas has been trading at a record high, and the ASX itself has been overwhelmingly up despite swings.
5.1 million passengers were on domestic commercial flights in Australia as of March, a figure sightly below the same time last year but more than four times the numbers in mid-2021.
Despite Virgin's voluntary administration in 2020 following Covid-19 travel restrictions, after which it was acquired by US private equity company Bain, it now corners 34.4 per cent of the domestic market share as of March 2025.
It is not lagging much behind Qantas, which holds 37.5 per cent, according to the Australian Competition and Consumer Commission.
The death of other budget airlines such as Bonza and Rex has only boosted these two major players. Qantas and Virgin have been boosted by the death of competing airlines, preserving their own market shares. NCA NewsWire / Nicholas Eagar Credit: NCA NewsWire
Virgin is also planning to resume long-haul international flights made possible by its partnership with Qatar.
The airline is conducting its IPO using a front-end book-building method, where investor bids are submitted before the prospectus receives approval from Australian regulators.
According to the term sheet, institutional investors were able to their bids up to Thursday, with the stock expected to begin trading on June 24.
Virgin's IPO will be the largest in Australia following the DigiCo Infrastructure REIT launch that raised $2bn in December before a 30 per cent downturn in share price.
Experts say the Virgin IPO could offer investors a unique entrance into the Australian airline market, but it has its own risks.
'Virgin Australia's planned return to the ASX via a $A685m initial public offering is the first major IPO of 2025, and one to watch closely,' eToro market analyst Josh Gilbert said. Experts are watching the major IPO closely. NCA NewsWire / Nicholas Eagar Credit: NCA NewsWire
'The IPO, priced at $A2.90 per share, gives the airline a market cap of $A2.bn. It follows the on-and-off IPO over the last two years when the airline sector has moved from strength to strength, with companies around the world announcing record profits and seeing shares rally.
'Under Bain's direction, Virgin Australia has streamlined operations, focusing on profitable domestic routes, and achieved record underlying earnings of $A439m in the latest half year.
'Essentially, it's a very different airline than it was in 2020 and it is far more attractive to investors. Having only one real competitor in the landscape, Qantas, makes the offer uniquely appealing.'
However, the investment could also be a major risk.
'Investors may view Virgin's IPO as an opportunity to gain exposure to Australia's duopoly airline market at a compelling valuation that will trade at a discount to Qantas,' Mr Gilbert said.
'Although the airline sector has had a great few years, investors should be mindful of its razor-thin margins and cyclical risks, particularly if demand slows amid slowing consumer spending.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News AU
an hour ago
- Sky News AU
US urges Australia and regional allies to increase military spending, warning that time is running out to deter Beijing
The United States has ramped up its call for a stronger military posture from Australia and its Asian allies, warning they cannot afford to lag behind while European nations dramatically boost their defence spending in response to global threats. With the 80th anniversary of the end of World War II in the Pacific looming, the Pentagon has issued a clear message - deterrence against China must become a collective priority. Senior US defence officials are looking to fortify military ties across the Indo-Pacific, with a pointed focus on Canberra and Tokyo. 'We need our allies to step up,' a US defence official told the Australian. 'How does it make sense for our Asian allies to sit back while the Europeans are stepping up and committing to 5 per cent of GDP to deal with Russia, which is one tenth the GDP of China?' While NATO members agreed in June to lift defence spending to five per cent of GDP, Washington sees Asian partners as lagging behind. South Korea has been singled out as a model ally, praised for its robust defence budget and substantial standing forces. Australia, by contrast, is facing criticism from US officials who argue Canberra is not investing enough, even to fulfil its commitments under AUKUS Pillar 1, which involves acquiring at least three US-built Virginia-class nuclear submarines. 'On defence spending, the objective analysis is that the Australian government is not spending enough on defence, even for Pillar I,' the official continued. 'This is a very real near-term problem. We have essentially no time in defence terms before 2027.' The year 2027 is viewed within the Pentagon as a key strategic benchmark, with intelligence suggesting Beijing could be in a position to launch an attempt to take Taiwan by then. In Washington, there's growing unease that Australia may not be pulling its weight. Prime Minister Anthony Albanese's recent Curtin Oration, in which he praised former PM John Curtin for resisting pressure from wartime leaders Churchill and Roosevelt, has reportedly triggered concerns among Trump-aligned figures. The speech was seen as a subtle signal of resistance to rising American expectations, especially in light of mounting calls for Australia to commit more resources to AUKUS and the wider regional deterrence posture. Inside the Pentagon, key strategic goals include strengthening homeland defence, reinvigorating the US industrial base, countering China's growing assertiveness, and ensuring allies 'do more to pick up slack'. The ongoing AUKUS review, led by Pentagon policy chief Elbridge Colby, is being described as 'fact-based, rigorous, and empirical'. It covers both Pillar 1 and Pillar 2, the latter focused on sharing advanced defence technologies with Australia and the UK. 'I think the main thrust of the review is to give people a real brass-tacks, clear-eyed understanding of where things stand,' a US official explained. Australia has already pledged $1.6 billion to support the US shipbuilding sector under the AUKUS framework.
News.com.au
an hour ago
- News.com.au
Morgans spotlights nine healthcare stocks with upcoming catalysts after 'upbeat' Bioshares Biotech Summit
Morgans' Scott Power describes mood at Bioshares Biotech Summit as "markedly more upbeat than prior years" with signs of a rotation back to ASX healthcare sector Power highlights nine ASX healthcare companies from summit with clear near-term catalysts over next three to six months Results from Argenica's phase II trial of lead product ARG-007 in acute ischaemic stroke patients expected in early September In a further positive sign the ASX healthcare sector may be recovering, Morgans' senior healthcare analyst Scott Power has returned from the 19th annual Bioshares Biotech Summit, describing the mood of presenting companies as "markedly more upbeat than prior years". The summit, which featured presentations from more than 30 biotech companies, followed a strong July for the healthcare sector, which rose 9.05% to be best performer of the 11 ASX sectors. While healthcare remains the worst-performing sector YTD, up just 1.81%, the solid July results and positive momentum at this year's Bioshares conference signals a positive turnaround. Attended by analysts along with institutional and high net worth investors, Stockhead's Tim Boreham refers to the summit as the "Druggies & Dealers' conference – a playful nod to the well-known annual Diggers & Dealers mining forum, which this year fell in the same week. "The conference was centred on the evolution and strategic positioning of Australian biotech companies across the drug development lifecycle, with a strong emphasis on innovation and commercialisation," Power said. "We generally got the sense there is a lot more happening in the background for many of these companies than first glance." Power has highlighted nine ASX healthcare companies presenting at the summit with clear near-term catalysts over the next three to six months. Morgans nine ASX healthcare stocks with upcoming catalysts Neuren Pharmaceuticals (ASX:NEU) Market cap: $2.2 billion Neuren develops drugs for the treatment of neurological disorders and became the darling of the ASX biotech sector in 2023 when trofinetide, marketed as DAYBUE, received US Food and Drug Administration approval as the first and only approved treatment for Rett syndrome – a rare neurological disorder mostly affecting girls and emerging in infancy. Acadia Pharmaceuticals, Neuren's partner, markets DAYBUE in North America with the Aussie biotech eligible to receive double-digit royalties payments. Power said the key upcoming catalyst for Neuren would be an expectation of continued improvement in DAYBUE net sales in Q3 CY25. The company's latest quarterly sales were US$96.1 million, up 14% on pcp. CogState (ASX:CGS) Market cap: $295.9 million Cogstate is a neuroscience technology company focused on optimising neurological health assessments to advance the development of new medicines and deliver clinical insights into brain function. Its Cognigram digital cognitive assessment system is used by physicians to monitor key aspects of neurological performance, including processing speed, attention, visual learning, working memory and executive function. CogState has provided FY25 guidance of revenue between US$52 to US$54 million, up 20% to 24% and profit before tax between US$12 to US$14 million. "CGS will report its FY25 result on August 22 with the existing share buyback expected to be extended," Power said. Market cap: $95m The key upcoming catalyst for Argenica is results forecast for early September of a phase II trial of its lead product ARG-007 in acute ischaemic stroke patients. ARG-007 is a synthetic peptide designed to protect brain cells from dying in the critical minutes and hours after acute neurological events such as stroke, traumatic brain injury (TBI) and hypoxic brain damage. In April, Argenica completed dosing of 92 patients in the double-blinded, randomised, placebo controlled phase II trial undertaken at eight emergency departments around Australia. Data-read out from the trial is due in September with safety the main endpoint, determining if the drug asset can advance further in clinical development. Blinklab (ASX:BB1) Market cap:$55m Blinklab is a company founded by neuroscientists at Princeton University and has developed a smartphone based diagnostic platform for autism, ADHD, schizophrenia and other neurodevelopmental conditions. "The key short term catalyst is the release of results for BB1's pilot study for autism involving around 190 children," Power said, "The study undertaken at two sites is on track to finish recruitment in August with data locking and unblinding to follow and results expected to be released in September. "A main phase trial is expected to follow recruiting up to 900 children across eight additional sites." Clever Culture Systems (ASX:CC5) Market capitalisation $62.4 million Adelaide-based Clever Culture Systems has developed the only US FDA-cleared AI technology for automated culture plate reading. Its APAS (automated plate assessment system) Independence instruments automatically analyse culture plates to detect microbial contamination, classifying growth as significant or non-significant. In sterile drug manufacturing, culture plates are used inside cleanrooms to monitor for contamination, with results critical to releasing safe and effective drugs. Clever Culture's APAS Independence reduces the time consuming manual analysing of the culture plates by microbiologists. "CC5 has signed up three large pharmaceutical companies including AstraZeneca, Bristol Myers Squibb and Novo Nordisk plus two large lab companies and is in negotiations with other tier one groups," Power said. "Announcements around additional customers or expansion with existing customers is a key short-term catalyst." Tetratherix (ASX:TTX) Market cap: $215 million Wound management house Tetratherix made its ASX debut on June 30, breaking an IPO drought for the sector. Barrenjoey Markets and Morgans Financial were joint lead managers and underwriters to the Tetratherix IPO. Tetratherix has developed a proprietary polymer platform enabling the targeted delivery of cells, drugs and biologics, to treat a range of conditions across tissue spacing, bone regenerative and tissue healing. The company will post its maiden FY25 result in late August. "The near-term catalysts we expect to be called out include progress on the bone regeneration franchise which is targeting FDA clearance in H2 CY26 and an update on the recruitment in the trial for Cohort 2 using TetraDerm (tissue healing) involving surgical incisions in the face and neck," Power said. Micro-X (ASX:MX1) Market cap: $52 million Micro-X has proprietary cold cathode, carbon nanotube (CNT) emitter technology which is focused on medical imaging and security applications. The company recently announced a significant commercial milestone, a three-year supply agreement with a major US healthcare provider for its Rover Plus mobile radiology system. The deal followed a successful evaluation and competitive tender by the healthcare provider, which operates more than 700 facilities nationwide. It has added Rover Plus to its approved procurement list, allowing member hospitals to purchase the system without further evaluation or tendering. "We expect additional supply agreements will be executed over the near-term," Power said. Dimerix (ASX:DXB) Market cap: $300m Dimerix's lead drug candidate DMX-200 is in a phase III trial for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. The ACTION3 phase III trial continues to recruit across clinical sites globally, with more than 190 sites activated. Full targeted recruitment of 286 patients for the ACTION3 trial is expected to be completed by the end of CY25. Dimerix is also developing DMX-700 for respiratory disease. "Following a positive interim analysis (Part 1) another interim analysis (Part 2) is expected to be released late CY25 or early CY26," Power said. Artrya (ASX:AYA) Market cap: $148m Artrya is developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software called Salix analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya has three key modules in its Salix platform. The FDA-cleared and launched Coronary Anatomy module is already in market. Power said upcoming catalysts for the company included FDA clearances of its Coronary Plaque module, expected in Q3 CY25, and its Coronary Flow module, anticipated in Q1 CY26. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
9 News
2 hours ago
- 9 News
The crucial factor that could soon cost every Aussie $14,000 a year
Your web browser is no longer supported. To improve your experience update it here Productivity: it's the crucial economic principle that has helped propel Australians into some of the best living standards in the world. But even as politicians and economists discuss it more and more, ahead of the federal government's crucial upcoming roundtable, it's something that many people still don't quite understand. So what actually is productivity, and why are experts so concerned with it at the moment? This is what you need to know. Productivity has driven the massive improvement in Australian living standards since mid-last century. (Edwina Pickles/SMH) Think of productivity as working smarter, not harder. Economically speaking, productivity is the amount of output you get from a set of inputs. Inputs are things like labour – often measured as the number of employees or number of hours worked – and capital, while output is the amount of goods and services produced. For a basic example, let's say a fast food outlet employs five staff, who work a combined 200 hours per week, and produces 5000 burgers over the course of that week. Its productivity would be 25 burgers per hour worked. So, put super simply, productivity is how much stuff you get from a set amount of effort. Productivity growth has been slowing in Australia and most other advanced economies. (Louie Douvis/AFR) Productivity itself isn't falling, but productivity growth is most certainly on the decline in Australia. The Australian Bureau of Statistics' (ABS) main, top-line measure of productivity growth has fallen substantially in recent years. In 2022-23, the 20-year average annual growth rate had fallen to 0.9 per cent, down from 1.2 per cent the year before and just half of the 1.8 per cent it was in 2003-04. It's important to note this problem isn't unique to Australia; just about every developed country is experiencing slowing productivity. Improved productivity is responsible for Australians' improved living standards. It leads to higher wages, more (and cheaper and better-quality) goods and services available, bigger profits for businesses, and overall economic growth. It also even paves the way for more leisure time; according to the Productivity Commission, the average Australian now spends five fewer hours at work every week than in 1960 due to better productivity. But if growth continues to slow, it puts all those benefits at risk. Improved productivity has allowed companies to produce more goods that are both cheaper and better quality. (Getty) To put a dollar figure on it, the Productivity Commission estimates that full-time workers will be $14,000 a year worse off by 2035 if Australia can't rediscover its previous growth and instead continues on its current trend. "The implications of that, I think, are already being felt," RBA Governor Michele Bullock said on August 12. "Real wages are not rising by very much, because that's the implication of slow productivity growth is that real wages can't grow as quickly. "If we can get productivity growth up, that will allow for more growth in real wages, which is ultimately good for Australians." Artificial intelligence has been touted as a potential productivity gamechanger. (Getty) While economists have been discussing productivity for decades – the Productivity Commission was established in the late '90s – a few developments have thrust it very firmly into the public eye. That came a week out from the federal government's productivity roundtable (officially the Economic Reform Roundtable), which was announced by Prime Minister Anthony Albanese in June. RBA Governor Michelle Bullock has warned Australians are already feeling the pinch of slowing productivity growth. (Dominic Lorrimer) The roundtable, to be held from August 19-21 in Canberra, will be a three-day discussion involving business and union leaders about how to address stagnating productivity growth. Many of the ideas put forward ahead of the summit have focused on tax (although AI, regulation, and even a four-day working week have also been discussed), following these comments made by Treasurer Jim Chalmers in June. "No sensible progress can be made on productivity, resilience or budget sustainability without proper consideration of more tax reform," he told the National Press Club. "I don't just accept that, I welcome it. Tax is one of many ways our three primary economic challenges are related." Treasurer Jim Chalmers flagged the economic roundtable could lead to tax reform. (Rohan Thomson/AFR) That's the trillion-dollar question. Albanese has been giving mixed messages, at one point ruling out any new tax reform ("the only tax policy that we're implementing is the one that we took to the election") and reminding everyone that he and his ministers get final say on any productivity solutions ("governments make government policy"). But the prime minister has also welcomed the glut of proposals he and Chalmers have been presented with, and has insisted he's "up for big reform" – although it might be something he takes to the next election in 2028. "We're up for discussion, and one of the things I said very clearly was we weren't going to get into the rule-in, rule-out game," he told ABC radio. "We have a big agenda. We were elected with a clear mandate on May 3. That's our priority, delivering on that. "But we're also up for ideas and we're up for things that can be done immediately. If they will improve the economy, then of course we'll give it consideration." Anthony Albanese has ruled out any new tax reform but at the same time said he's open to big ideas. (James Brickwood) Respected economist Richard Holden, who along with independent MP Kate Chaney proposed a revised GST model for the roundtable , said it was crucial that proper reform does come out of the summit. "That's the question: is the upcoming August 19 roundtable going to be a moment for genuinely thinking about bold ideas?" he said. "Or is it going to be another one of these pro-forma... we have three days, we'll put out a press release and we go back to normal? "I hope it's the former." CONTACT US Property News: Rubbish-strewn house overtaken by mould asks $1.2 million.
